S. Kasibhatla

发表

Structure-guided design of AMP mimics that inhibit fructose-1,6-bisphosphatase with high affinity and specificity.

W. Lipscomb, M. Erion, Q. Dang, 2007, Journal of the American Chemical Society.

Orally active purine-based inhibitors of the heat shock protein 90.

S. Kasibhatla, A. Kamal, J. Sensintaffar, 2006, Journal of medicinal chemistry.

7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.

S. Kasibhatla, Y. Ran, A. Kamal, 2006, Journal of medicinal chemistry.

Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.

M. Erion, Q. Dang, S. Kasibhatla, 2011, Journal of medicinal chemistry.

AMP deaminase inhibitors. 5. Design, synthesis, and SAR of a highly potent inhibitor series.

M. Erion, S. Kasibhatla, W. Xiao, 2001, Journal of medicinal chemistry.

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

S. Kasibhatla, Y. Ran, L. Fritz, 2007, Journal of medicinal chemistry.

Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.

M. Erion, Q. Dang, S. Kasibhatla, 2010, Journal of medicinal chemistry.

MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes

Tao Jiang, M. Rami Reddy, Mark D. Erion, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.

W. Lipscomb, M. Erion, Q. Dang, 2007, Journal of the American Chemical Society.

AMP deaminase inhibitors. 3. SAR of 3-(carboxyarylalkyl)coformycin aglycon analogues.

M. Erion, S. Kasibhatla, J. Appleman, 2000, Journal of medicinal chemistry.

EC144 is a potent inhibitor of the heat shock protein 90.

S. Kasibhatla, I. Enyedy, C. Ambrose, 2012, Journal of medicinal chemistry.

BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models

S. Kasibhatla, Hong Zhang, A. Kamal, 2007 .

Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors.

L. Petrucelli, S. Kasibhatla, M. Hutton, 2005, Current Alzheimer research.

Abstract LB-118: SR8541A is a potent inhibitor of ENPP1 and exhibits dendritic cell mediated antitumor activity

S. Kasibhatla, Sunil Sharma, M. Kaadige, 2020 .

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

S. Kasibhatla, Hong Zhang, R. Scannevin, 2009, Molecular Cancer Therapeutics.

Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.

M. Erion, Q. Dang, S. Kasibhatla, 2008, Journal of medicinal chemistry.

AMP deaminase inhibitors. 2. Initial discovery of a non-nucleotide transition-state inhibitor series.

M. Erion, S. Kasibhatla, J. Appleman, 2000, Journal of medicinal chemistry.

Design and synthesis of the first potent, selective, and cell penetrating adenosine 5'-monophosphate deaminase inhibitors.

M. Erion, S. Kasibhatla, J. Appleman, 1998, Advances in experimental medicine and biology.

DISCOVERY OF AMP MIMETICS THAT EXHIBIT HIGH INHIBITORY POTENCY AND SPECIFICITY FOR AMP DEAMINASE

M. Erion, S. Kasibhatla, J. Appleman, 1999 .